ClinicalTrials.gg
RecruitingNCT07940387Updated Nov 16, 2026

IV Lidocaine in Ortho Trauma Patients

A Phase 1 interventional study of Lidocaine infusion and Saline (0.9% NaCl) in Orthopedic Fractures, sponsored by Wayne State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Wayne State University · Phase 1, Interventional, and Supportive care

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.

02

Conditions studied

  • Orthopedic Fractures

Browse trials for

Keywords

  • orthopedic fractures
  • IV lidocaine
  • trauma
  • interleukin
  • complement
03

In context

Wounds and Injuries

2,218 studies on the registry are indexed under Wounds and Injuries; 440 are open to participants now.

This study's planned enrollment of 66 is close to the median of 70 across 1,423 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Wayne State University is the lead sponsor of 231 studies on the registry; 36 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- I-III, males and females >18 years of age and \< 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.

Exclusion criteria

Exclusion Criteria:

  • to lidocaine including allergy, substantial hepatic impairment ( greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.

Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of \<95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
66 participants (estimated)

Study arms

  • Placebo comparator
    Control Group - Saline Infusion

    Saline bolus and infusion

    Drug: Saline (0.9% NaCl)

  • Experimental
    Intervention - IV Lidocaine Group

    Lidocaine bolus and infusion

    Drug: Lidocaine infusion

Interventions

  • A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr.

  • DrugSaline (0.9% NaCl)

    Saline infusion

06

What researchers measure

Primary outcomes

  1. Morphine equivalents

    Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period

    Time frame: from enrollment to 14 days postoperative

  2. Interleukin 6 (IL-6)

    Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL

    Time frame: 1, 6, 24 and 48 hours postoperative

  3. Interleukin 8 (IL-8)

    Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL

    Time frame: 1, 6, 24 and 48 hours postoperative

  4. Complement C3a

    Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL

    Time frame: 1, 6, 24 and 48 hours postoperative

  5. Visual Analogue Pain Score

    Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever.

    Time frame: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.

Secondary outcomes

  1. Quantitative Sensory Testing

    Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia

    Time frame: Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)

07

Study locations

1 of 1 sites recruiting
  • Detroit Receiving Hospital
    Detroit, Michigan 48201, United States
    Recruiting
    • Jessica Phillips, PhD, CRNA · Contactfy9015@wayne.edu · 313-577-9239
    • Mary Golinski, PhD, CRNA · Contactgolinski@oakland.edu · 248 364 8776
    • Jessica Phillips, PhD, CRNA · Principal investigator
    • Mary Golinski, PhD, CRNA · Principal investigator
    • Wael Saasouh, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 16 phase 1 interventional studies under Wounds and Injuries, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 62. This study's planned 14 months is below that.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940387
Responsible party
Jessica Phillips (PhD, CRNA, Wayne State University) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 16, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion